drugset / Trial / NCT07054034
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
Timeline
- Start
- 2025-05-11
- Primary completion
- 2026-05-26
- Completion
- 2027-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MG-ZG122 | Monoclonal antibody | 210 mg | Subcutaneous |
| Subject | MG-ZG122 | Monoclonal antibody | 420 mg | Subcutaneous |